New drug aims to save premature babies' eyesight
NCT ID NCT07093255
First seen Apr 24, 2026 · Last updated Apr 24, 2026
Summary
This early-stage study tests a new medicine called FLQ-101 in 18 premature babies born at 26-27 weeks who are at high risk for retinopathy of prematurity (ROP), an eye disease that can cause blindness. The main goal is to check the drug's safety and how the body processes it. Researchers will monitor side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY (ROP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. David's Medical Center
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.